Aura Biosciences, Inc. (AURA) stock
AURANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.11−0.50 (-6.57%)
Close on Nov 12, 2026Market cap $737.34MP/E –Yield –
Aura Biosciences cash
Cash and short-term investments held at the end of each period.
Aura Biosciences's cash was $41.67M at Sep 30, 2026. For fiscal 2025 it was $144.20M, up 355.0% from the year before. The highest annual figure on record is $188.80M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $144.20M | +355.0% |
| FY2024 | Dec 31, 2024 | $31.69M | -22.8% |
| FY2023 | Dec 31, 2023 | $41.06M | -78.3% |
| FY2022 | Dec 31, 2022 | $188.80M | +26.7% |
| FY2021 | Dec 31, 2021 | $149.06M | +757.0% |
| FY2020 | Dec 31, 2020 | $17.39M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $41.67M | -12.4% |
| Q2 FY2026 | Jun 30, 2026 | $67.84M | -36.8% |
| Q1 FY2026 | Mar 31, 2026 | $84.79M | +121.8% |
| Q4 FY2025 | Dec 31, 2025 | $144.20M | +355.0% |
| Q3 FY2025 | Sep 30, 2025 | $47.55M | +87.2% |
| Q2 FY2025 | Jun 30, 2025 | $107.37M | +257.0% |
| Q1 FY2025 | Mar 31, 2025 | $38.23M | +45.5% |
| Q4 FY2024 | Dec 31, 2024 | $31.69M | -22.8% |
| Q3 FY2024 | Sep 30, 2024 | $25.41M | -83.0% |
| Q2 FY2024 | Jun 30, 2024 | $30.08M | -81.4% |
| Q1 FY2024 | Mar 31, 2024 | $26.28M | -84.9% |
| Q4 FY2023 | Dec 31, 2023 | $41.06M | -78.3% |
| Q3 FY2023 | Sep 30, 2023 | $149.10M | +33.7% |
| Q2 FY2023 | Jun 30, 2023 | $162.00M | +32.7% |
| Q1 FY2023 | Mar 31, 2023 | $173.50M | +30.2% |
| Q4 FY2022 | Dec 31, 2022 | $188.80M | +26.7% |
| Q3 FY2022 | Sep 30, 2022 | $111.50M | +36.3% |
| Q2 FY2022 | Jun 30, 2022 | $122.10M | +32.4% |
| Q1 FY2022 | Mar 31, 2022 | $133.30M | +33.7% |
| Q4 FY2021 | Dec 31, 2021 | $149.06M | +757.0% |
| Q3 FY2021 | Sep 30, 2021 | $81.83M | +624.0% |
| Q2 FY2021 | Jun 30, 2021 | $92.20M | – |
| Q1 FY2021 | Mar 31, 2021 | $99.67M | – |
| Q4 FY2020 | Dec 31, 2020 | $17.39M | – |
| Q3 FY2020 | Sep 30, 2020 | $11.30M | – |
See a number that looks wrong?